Trastuzumab
- Level
- Commodity
- Parent
- 51111700
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51111717This classification denotes a monoclonal antibody with the molecular formula C6470H10012N1726O2013S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P188ANX8CK, more generally known as trastuzumab. European Medicines Agency schedules trastuzumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12612MIG. The term TRASTUZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40. TRASTUZUMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule trastuzumab under HS 30021091 and SITC 54163. As of Q4 2014, TRASTUZUMAB remains the US FDA Preferred Term for this commodity. Trastuzumab bears US NLM identifiers UMLS ID C0728747 and NCI Concept Code C1647. SMILES: CC(CCC(=O)O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C.
Same parent
Under 51111700 · 67Activities that produce or sell this
KBLI · 8Inherited from family 51110000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.